Google
Trusted Resources: News & Meetings
Latest announcements and gatherings
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
myBinderRelated Content
-
He Inherited A Devastating Disease. A CRISPR Gene-Editing Breakthrough Stopped ItPatrick Doherty had always been very act...
-
Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022Intellia Therapeutics, Inc. (NASDAQ:NTLA...
-
First Gene-Editing Treatment Injected Into the Blood Reduces Toxic Protein for up to 1 YearThe first team to disable a disease gene...
-
With CRISPR Gene Editing, Unique Treatments Begin to Take off for Rare DiseasesIn February last year, Doherty — now a...
-
CRISPR’s Quest to Slay Donegal AmyIn the 5th century, in early medieval Ir...
-
The Canadian Amyloidosis Support Network, Inc.The Canadian Amyloidosis Support Network...
-
Amit R. Patel, MDDr. Amit R. Patel is Professor at UVA He...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Community Key Collaborator
Support for this landing page is provided by an independent education grant from
Translation of this platform made possible through an independent education grant from
Powered by
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
